SinuNase
Phase 3- Indications
- Chronic rhinosinusitis
Company intelligence / Profile preview
Respirics, Inc.
Raleigh, North Carolina, United Statesconcentrxpharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 3
01
Overview
Developed and commercialized the MD Turbo™ device which was marketed in the United States by TEAMM Pharmaceuticals
- Therapeutic areas
- Pulmonology
- Modalities
- Inhalation drug productsDry powder inhalers
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
TEAMM Pharmaceuticals, Inc. (a subsidiary of Accentia Biopharmaceuticals, Inc.)
Beyond the preview
Go deeper on Respirics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Respirics, Inc..